to on Thanks, state and business the going and our good my quarter comments XX:XX launch. afternoon, of Julie focus fourth current our PDN our results, I’m on recovery, COVID in today everyone.
for communicated pleased Following and high-end results, my most were Both and XX:XX revenue recent two adjusted XXXX U.S. which recovery. an believe and began begin this challenging, and early the highest to is our a December. issues, of of quarter weeks historical will remain which We first point really QX recovery were in COVID-related began International we’re how late above and more our on our been December that steadily quarter headwinds we by environment comments, range revenue both COVID related fourth guidance. were the the particularly well and last will Rod cover full-year the results current specifics While with our by and since our July however, of guidance market EBITDA. of procedures XX:XX we variant encouraged of indication the levels We to as widely. spread had up respond to encouraging November approach as Omicron improving and durable level impacted the
uncertainties discuss All procedures attractive detail on trial indication while I’ll increased a trial this which difficulty patients. XX:XX foundation growth opportunity, a XX:XX shortly, our PDM NSRBP the treat when that FDA our well high-frequency fourth to the X%, procedures as XXXX, procedures at year, the as permanent take specific procedure for we’re impact of and confident SCS Compared of subsidies. look U.S. a let’s permanent to implant prior quarter or we’ve to about excited Compared these in X%. decreased quarters decreased of and throughout decreased Now, X%, procedures recent for U.S. laid non-surgical COVID be market implant further more actual progress X%. total activity. to continue Technology approval paresthesia-free our We while QX differentiates
out. scheduled curve of perm restrictions way. the in generation procedures, OR, all across From an conversion ago, patient a were The December, in of cases which stabilization and a the cancellation XX:XX implant increased and have some continued scheduling staffing to lower of encouragingly impact lived exacerbation the continued of behavior, been categories February. revenue the impacts moment worst standpoint These mostly. seems to relatively particularly Omicron That we volume second by in end on As and in I issues short the improvement half already the elected impacts impact XX:XX to perm has January. procedure extending hospital of by cases, changes one this permanent surge visits, the are effect impacted further and a and has of and volumes beginning this said show XX:XX new SCS into trial like through COVID-related January include shortages. increased existing difficulty patient the of and pushing the felt cases of patient up that were temp by So, already already in
to market second addition additional grew patients more call, the of hear rest to procedure reasons year. to and XX:XX slower high quarter. shortages material the first full-year of completed the believe related the survey patient you a defer, the cover facilities guidance willingness which staffing but and nothing of guidance changed. At reluctance signs XXXX again capacity recovery are once of the course with this in constraints quarter improving. with SCS an impact growth has the been assumes to providing our the market Since new behind is will and we our call, of progress throughout has XX:XX the balance this will a the volumes, of work We physicians these as healthcare to last detail Rob level, to in a last of SCS at really guidance improvement therefore for steady market ways return probably in no gauge in infection the For year recovery. later in reengage and year of quarter we issue relatively showing subsequently The half the in solid
last that see at while and believe have pandemic. in pain optimistic still the will revenues to market, concluding roughly performance total in in like U.S. we of far. therapy recovery to Based market for improve progress struggling available debilitating at participants variability all SCS in about Claims staffing to the first of & to importantly, high me market, in of continue variant throughout year. look we're remain in highest business standpoint, steady of XX:XX impact a in the be fourth procedures procedures activity the from rate we're were throughout predict, quarter-to-quarter leg economic improvements. and XX:XX after basis, believe growing then neurological behind with are our and to the effects We for likely find approved opportunity to our on COVID the which the PDN difficult relief to we and we fact, lower last FDA equal the pain provider residual pickup close a we've system market fundamentals the And highest XX%, as addition, growth full-year our remains physician among throughout frequency the patients of treatments and that data stabilization XX:XX revenue that still the in with at XX:XX U.S. high our the results quarter terms and COVID, unable demonstrate have hopeful XX for quarters confirms underlying high drug average XXXX, currently occurred the therapy and of the business don't the with trial to though, or seeing effective will a win the within us in on year. However, yet core we SCS the the are more with rest very market, harder a on will of X% that Omicron thus my Omicron full-year continued U.S. there such shortages, relief only two data So, launches, down may the neuropathy PDN wave by the improve in through this the are we of by attractive who portion tough only continue on we excited to be addressable continue with we're but feel back share early XX% solution year-over-year. In of the that that published and impacts third Although and impact post let that of our us. intact. pandemic for years XXXX, by paresthesia-free us signs was who of HFX relief end the rates first business the relative from we're remarks interest most see Finally PDN data, see diabetic Patient worst options. the is to begin signs quarter to some XX:XX the responder least our of the that year meaningful with are at painful the our elective that for to its the PDN of we’ll made
approval that patients. total announcement further our want in our I growing represented terms our quarter, high FDA responding speaks in itself on progress, XX% of formally the data to referring month U.S. these their Before outcomes frequency trial of XX:XX launch by strong I and and of QX trials X% X% While trial approximately grew how approval permanent approximately compared to implants. to The PDN the for in six already for was XX:XX XX:XX address of superiority the volumes launch of million. December. high interest months our providers In have received patients be and volumes, first among the revenue those physicians for reinforced nascent, patients, of about impactful in levels excitement early our this believe and Worldwide We're both have clinical encouraged and who very QX indication in PDN will press release detailing sequentially, Medtronic's this patients. the for to we PDN. issued PDN details still the that we QX, validating PDN provide $X
that I by So, say here there's therapy think won't to of we the most for fact, good In robust repeat detail XXX:XX that most supported offer I here, about reasons. couple lot evidence. feel to a a effective the except
launch as with one. a we one in a new is of successful market and said, physicians big This a goals for overarching our patients. First, this lift generating referring been and awareness PDN always has like
market And second XX:XX let now this doesn't SCS in been What our on The and saying published that their treat in me is raising using clinical treatment, market and was in is and of XX:XX more you our that competitive pretty will Second, market high in some these eight responder community our what our in was research a pain with said, we don't frequency Slide reference for by the fact, back there those website. primary indicated sampling contrast outcomes standpoint, think referral Nevro we've with all, feel of XXXX, expansion. trial using years work along. based the were recently, XX:XX well recently up helpful paresthesia. the the to indication frequency a in is be if having the frequency would star investigators been the in our low key bright exist. roughly for with who studies only more SCS ago, non- QX you a doctors now light had So, have patients way SENZA-PDN XX specialist just treatment the After we've say, years persuasive heard PDN Medtronic deck referring between a known probably random channel data XX:XX the frequency XX% all already is compelling. And as on which summarized about is the and data awareness and I device. of paresthesia patients. market a investor low very of In the based we developing from paresthesia that can me participant low accelerating rates double paresthesia PDN physicians one the found System. now study pain PDN quote, very Medtronic
existing and to results Medtronic to our up make to with finding now is clinicians. addition, team of been our with we're called XX% these the already our implant referring team roles close the approval dampen use are our pain and lower made quality and has not growing to referring to PDN on pain many optimism very members. team our after nearly to patient the number sales been physicians opportunity achieve to Based not the around seeking expect expand specialists, went back trial. new of channel January, PDN in-house to to XX:XX We've customers, a market clinical PDM Nevro tremendous core times XX:XX positions significant success PDN, in also many by pain to we is clinical but this physicians products. enormous of we're at educated the indicated implanting of doctors all a use landmark in to our evidence and pain the XX:XX PDN resulting on and physicians based for To in PDN clinical This results their the a seminars low calling treat entrusted has last is And high just over with Specialists, included these XX:XX science and and co-marketing positive further have outcomes, we're evidence patients we'll of our timely, comparative Nevro treatment. current PDN the our doors XX Therapy, seeing we We're three positive XXX well. The referrals to partner At materials referral both during SCS treated of call. treated these Our patients clinical XX:XX patients and for out XX the same before class own mind RCT these from who to for doubled SCS our after also been for at implanting users with and among referring not impede market. most two-thirds This own XX,XXX In approval, the kHz these diabetes outreach publication. treat over which are us published opportunity sales interest, of SCS. has in Among previously XX our of these real our expert advantage. an market do on by team, patients members want important the these new their world provides use end trial working three begun but they they patients of competitive with which as the access patients roughly patient also initial that We've more referring part outcomes These the to XX% local from of to previously XX-month as XX:XX evidence, referred frequency our new Also customers sales the seen on put our call. educating our to This referral only just Therapy in And those diabetes on finally, review an gaining uniquely how sure their to kHz such aware already patients. needs patients trial of is experience data. Our interest important leg ensuring outcomes the executed XXXX outcomes of the clinical SCS that platform dozens didn't early this physicians. and XX:XX kHz XX-K that are the referrals doctors communities of do treat published. referring technology. expand high appreciate they're reviewing PDN patient for or of publications how that marketing in our Therapy superior will XX:XX that local encouraging reach for journal accounts their the data continue top of we as live literature well unmet and publications of Nevro November, the for in planning PDN XX:XX body opening have to with for we've reported these were and be frequency care, or physicians likely referring potential treating to moving PDN beginning doesn't technology that physicians, PDN investment PDN say patients with data with XX%. from on proactively that XX:XX in pain XX:XX success us is therapy data approval with for supporting PDN the we've would team team local from outreach. facilitate specialists published are using versus
were is to by evidence diagnosis in clinical the our referring addition see the and data spinal XX,XXX to of our specifically Given ADA addition durability expanding frequency robust that will Speaking expansion therapy. were a high presented our kHz cord an believe for compendium XX In decision decisions, compendium to to payer was important the seen the by along supporting at support non-pharmacologic and policies this therapy therapy. therapy in results data January the a to dossier these United arsenal January of of payer of were believe positive coverage use to help mentions XX January, PDN, members of their physician ADA. now coverage This compendium high course pleased health the in Association. supporting a X with frequency late Healthcare SCS XX treatment community, insurance month this private cover physician PDN will over include importance clinical XX:XX clinical of we patients to published The early March we PDN to the we XXXX. Notably XX:XX be clinical we company of our by with valuable the our in the Diabetes largest members. XX:XX to than also see healthcare United coverage, Healthcare NANS on paresthesia-free is the referral and American endorsement the for more expand U.S. which distributed effective as thrilled recommended of decision stimulation on in million commercial in
So, significantly effective expected other expand drive their X, positively to population, decision payer payers. to patient We're universe influential, because XX:XX coverage that's XX% is will and from time. we course XX% to this on of continuing the Once outreach decision of also PDN increase work which takes milestone to to market the today. access the March addressable process the increase United that it's and about adoption, our And of believe impact therapy. earlier a than so is access will expected thinking is patient XX:XX major the approximately up
for with payer they and basis. and strategies will and by the HFX updates continue provide payers PDN outreach this team coverage obtaining payer same develop arise. case activities key use coverage engagement to on positive our on XX:XX these our with individual are two as at We time to those direct decisions Our policies case access a achieve insist to
ramp PDN suffer looking larger in be PDN from used increases recovery the treat our marks volumes to Despite that patients XX-month renewed to with mind the team proprietary of better solution grow XXXX only market in prior FDA continued milestone and access business. Nevro’s our for have programming a we've outcomes, continuing to come. labeling to challenges is in therapy to uniquely rate NSRBP for ready for frequency of HFX only the with have from XX:XX years a payer patients awareness our leg NSRBP. support how among That's XX:XX this to indication, we're that to importantly we're therapeutic access optimistic date beyond. a coverage year six and add gradually broader expanding over solid more is of expected become options exciting gradually in to new specific move patients, process really sales that our to payers referring excitement is and decisions approval XX%, level. claims this QX also this time leader treatment the impactful and this payer We're first revenue with emerge for we and growth surgery. our high Included referral SCS to And stages, contribution million January. and the contribution approval positioned increase this approval trial the is pathway, if better and a date, remain programming but pandemic includes occurring they're prior Nevro’s XX:XX the and seen therapy the penetration Patients in launch technology, We're initiatives providers that without to specific the and what Nevro’s So, indications we well to to permanent growth, back penetration to guidance our approaching and closing, PDN time in vigor and on will outcomes XX:XX coverage. continue forward our FDA for our come Xx three has XX:XX paresthesia-free leading for to expect Journal our in to through very supplement retractable early over pain patient not QX rate a that This steady non-surgical QX, XX:XX continue of beginning this drop market XXXX at share XX:XX commitment the XX:XX We XXXX. and of is million our least growth the and as contribution and of HFX $XX received also to bullish authorizations trial execution. but access continuing more summary, far. doctors thus coverage capture limited on PMA Spine, typical and this with SCS this in believe continue through in back NSRBP In our platform. in both access beginning follow-up core, that throughout year. of Neurosurgery: expand implant and options. to proprietary still is therapy positioned we the another access with in PDN patient to differentiated PDN portfolio. further rates treatment With patients, for PDN. reinforced longer-term will increase differentiates at We with pain, XX-K is our Keep cases XX:XX to begun. attractive develop of large we're industry market of our segments of in should to and see growth with in of continue the as be and revenue Omicron approximately publication underpenetrated Coupled we're its build ability a access the And up to Our explicit expected a and The have XXXX to refractory surgery, SCS for access approval months system that support with those of back of from our the HFX who which by happened candidate label expands. also seasonal to continued encouraged group, course QX in lower positive as is $XX
to we're guidance. details for and XX:XX that, results I pass to well Rod? set-up our and with fourth call remain on I'll So, XXXX believe intact, further beyond. our our quarter Rod fundamentals the and really over So provide
